For most patients with metastatic disease, the initial treatment regimen consisted of taxanes and anti-HER2 monoclonal antibodies (3, 60%) and hormone therapy alone or in combination for the two patients (40%) with hormone receptor-positive tumours (Table 4). The gene discussed is ERBB2; the disease is neoplasm.